New York, USA - March 13, 2023 - Navigating the focus of attention in February and March across the scientific community is the latest NIH's COVID-19 research released in the journal Science, reflecting on critical insights into responses against future pandemics. Even if the COVID-19 epidemic is leveling off on a global basis, with efficacious preventive vaccines and therapeutic drugs available, studies cannot halt as the virus is evolving and more measurements are needed to curb any possible massive outbreak.
Research advancements can never stand alone from collaborative efforts of the scientific community during the past three years, so as forefront CROs that output critical reagents and provide innovative technical supports. Creative Biolabs is one among the group aiding the research on SARS-CoV-2 and the exploration of COVID-19 therapies since December 2019.
"We now have established a complete line of action," according to a specialist who served during the MERS epidemic and was involved in the refinement of Creative Biolabs drug discovery service pipeline, "which can fulfill any research objectives around new drug discovery and evaluation."
Its drug discovery services cover antiviral drug discovery, vaccine discovery, and high-end evaluation platforms.
There are several vaccines and boosters on the market available for preventive usage developed by pharmaceutical giants like Pfizer, Moderna, and Johnson & Johnson. However, the competition for exploring more potent solutions, including therapeutic strategies other than mRNA vaccine, is fierce. From design all the way to SARS-CoV-2 vaccine analysis, customers can find corresponding solutions at Creative Biolabs.
"The current research focus is mainly placed on antiviral drugs. We can help in the development of SARS-CoV-2 spike and N protein aptamers with high-affinity, which are handy tools for antiviral drug discovery," added the specialist, "and are verified to bind to target proteins in SPR detection."
With more drug candidates entering pre-clinical discovery, Creative Biolabs has also leveraged its banks of animal resources covering rodents and NHPs to accommodate SARS-CoV-2 model development catering to the increasing demands on drug validation and medical countermeasure research.
Learn more about Creative Biolabs' endeavors at https://sars-cov-2.creative-biolabs.com.
About
Creative Biolabs has supported coronavirus research and made contributions to past pandemics-SARS and MERS-by instantly reacting to the COVID-19 outburst and providing comprehensive solutions and necessary reagents that joined studies involving prevention measurements and therapeutic routes. For the first quarter of 2023, Creative Biolabs upgraded its services and product portfolios, aiming to give first-hand assistance to global scientists during the exploration of potent therapies.
Media Contact
Company Name: Creative Biolabs
Contact Person: Candy Swift
Email: Send Email
Phone: 1-631-830-6441
Country: United States
Website: https://sars-cov-2.creative-biolabs.com
